Frequency bags $62M to advance Astellas-partnered hearing loss drug

Frequency bags $62M to advance Astellas-partnered hearing loss drug

Source: 
Fierce Biotech
snippet: 

Frequency Therapeutics has raised $62 million to take its Astellas-partnered hearing loss drug into phase 2a. The series C is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.